Larimar Therapeutics Inc (LRMR)

$9.32

-0.01

(-0.11%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $9.22
    $9.63
    $9.32
    downward going graph

    1.12%

    Downside

    Day's Volatility :4.3%

    Upside

    3.22%

    downward going graph
  • $2.18
    $13.68
    $9.32
    downward going graph

    76.61%

    Downside

    52 Weeks Volatility :84.06%

    Upside

    31.87%

    downward going graph

Returns

PeriodLarimar Therapeutics IncIndex (Russel 2000)
3 Months
45.63%
0.0%
6 Months
118.78%
0.0%
1 Year
198.72%
0.0%
3 Years
-5.86%
-19.4%

Highlights

Market Capitalization
595.3M
Book Value
$3.62
Earnings Per Share (EPS)
-0.96
Wall Street Target Price
25.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-17.32%
Return On Equity TTM
-26.75%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-50.5M
Diluted Eps TTM
-0.96
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.31
EPS Estimate Next Year
-1.98
EPS Estimate Current Quarter
-0.23
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Larimar Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 168.24%

Current $9.32
Target $25.00

Technicals Summary

Sell

Neutral

Buy

Larimar Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Larimar Therapeutics Inc
Larimar Therapeutics Inc
22.79%
118.78%
198.72%
-5.86%
-24.23%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Larimar Therapeutics Inc
Larimar Therapeutics Inc
NA
NA
NA
-1.31
-0.27
-0.17
NA
3.62
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Larimar Therapeutics Inc
Larimar Therapeutics Inc
Buy
$595.3M
-24.23%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Larimar Therapeutics Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 206.5%

Institutional Holdings

  • Deerfield Management Co

    33.28%
  • RA Capital Management, LLC

    9.48%
  • HHG PLC

    6.30%
  • Blue Owl Capital Holdings LP

    6.26%
  • Goldman Sachs Group Inc

    5.36%
  • Vanguard Group Inc

    3.71%

Company Information

larimar therapeutics, inc. (nasdaq:lrmr), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. the company’s lead compound, cti-1601, is currently being evaluated in a phase 1 clinical program as a potential treatment for friedreich’s ataxia, a rare and progressive genetic disease. larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. for more information, please visit: https://larimartx.com.

Organization
Larimar Therapeutics Inc
Employees
42
CEO
Dr. Carole S. Ben-Maimon M.D.
Industry
Health Technology

FAQs